
About Sudarshan Pharma
Sudarshan Pharma is a publicly listed company based in Mumbai (India) founded in 2008. Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals. It operates on a B2B2C and Reseller / Distribution model. The company has 24 employees. Sudarshan Pharma has completed 1 acquisition, including Ishwari Healthcare. Its Indian entity Sudarshan Pharma Industries Limited reported revenue of βΉ712 Cr. Sudarshan Pharma offers products and services including Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing. Its focus areas include Pharmaceuticals, Active Pharmaceutical Ingredients, Chemicals and Specialty Chemicals.
Company details
Sudarshan Pharma Industries Limited is involved in the production of pharmaceuticals and specialty chemicals. Operations are focused on active pharmaceutical ingredients (API), intermediates, and contract manufacturing. The company serves various sectors including healthcare and industrial applications. Solutions are provided for ethical divisions, generic supply, and institutional markets. Manufacturing facilities are located across multiple states in India, with distribution outlets in key regions. Exports of APIs and formulations are also managed to international markets.
- Headquarters Mumbai, India
- Employees 24
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website sudarshanpharma.com
- Social LinkedIn X Facebook
- Legal Name Sudarshan Pharma Industries Ltd
- Market Cap₹800 Cr
SUDARSHAN · NSE
- Share Price₹31.42
-0.10% today
- Revenue₹703 Cr
FY 2025-26 · +39.2% YoY
- EBITDA₹51.32 Cr
Margin 7.3%
- Net Profit₹23.31 Cr
FY 2025-26 · +29.3% YoY
- P/E (TTM)28.7x
P/B 4.3x
- ROE16.3%
ROCE 15.1%
- Debt / Equity1.60
Interest cover 54.1x
- Latest Funding Round$449.92K (USD), Post-IPO
Dec 2024
- Employee Count24
- Investments & Acquisitions
Associated legal entities of Sudarshan Pharma
Sudarshan Pharma operates through Sudarshan Pharma Industries Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Limited Listed CIN L51496MH2008PLC184997 | Active | 23 Jul 2008 | Mumbai, Maharashtra | ₹712 Cr | 9 | 9 | View details |
Products & Services of Sudarshan Pharma
Sudarshan Pharma offers a comprehensive portfolio of products and services, including Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing.
Specialty chemicals are manufactured for diverse industrial applications.
Active pharmaceutical ingredients are produced for medicinal purposes.
Manufacturing services are provided for pharmaceutical and chemical products.
Chemical intermediates are produced for further industrial processing.
Funding Insights of Sudarshan Pharma
- Total Rounds 1
- Last Round Post-IPO β $449,920
- First Round $449,920
(Dec 2024)
All 1 funding rounds of Sudarshan Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $449,920 | Post-IPO | β | β | β |
Board of directors of Sudarshan Pharma Industries Limited (Sudarshan Pharma)
Sudarshan Pharma Industries Limited is the primary company behind Sudarshan Pharma. The board of Sudarshan Pharma Industries Limited currently have 7 directors; the longest-serving is Sachin Vasantrai Mehta, appointed in 2008. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sachin Vasantrai Mehta DIN 02211178 | Managing Director | 23 Jul 2008 | 18 yrs 3 mo | Sudarshan Pharma Industries Limited |
| Hemal Vasantrai Mehta DIN 02211121 | Managing Director | 16 Jan 2015 | 11 yrs 10 mo | Sudarshan Pharma Industries Limited |
| Jaya Ankur Singhania DIN 01990322 | Director | 27 Dec 2022 | 3 yrs 10 mo | Sudarshan Pharma Industries Limited |
| Rushabh Prashant Patil DIN 09779021 | Director | 21 Jul 2023 | 3 yrs 3 mo | Sudarshan Pharma Industries Limited |
| Anil Balkrishna Ghogare DIN 00432659 | Director | 10 Nov 2023 | 3 yrs | Sudarshan Pharma Industries Limited |
| Vijay Ojha DIN 02216129 | Director | 18 Oct 2025 | 1 yr 1 mo | Sudarshan Pharma Industries Limited |
| Vinay Kumar Pandey DIN 10084203 | Director | 01 May 2026 | 6 mo | Sudarshan Pharma Industries Limited |
People of Sudarshan Pharma
2 people are tracked at Sudarshan Pharma (2 in leadership); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
| Managing Director | Leadership |
Complete people profiles for Sudarshan Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sudarshan Pharma
Sudarshan Pharma is a publicly listed company on the BSE with ticker symbol SUDARSHAN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Mar 2023
- Listed onBSE: 543828
- Listed entitySudarshan Pharma Industries Ltd
- Exchange sectorHealth technology
- ISININE00TV01023
- Share price₹37.31 (-0.43% on the day) · 2026-10-14
- Market capitalisation₹935 Cr
- Price to earnings35.2
- EPS (diluted, trailing year)₹1.06
- Volume (last session)24,000
Financials of Sudarshan Pharma
Exchange-reported figures of Sudarshan Pharma Industries Limited, the listed company behind Sudarshan Pharma (NSE: SUDARSHAN).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 703 | 505 | 464 | 461 | 357 | 193 | 148 |
| Revenue growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| EBITDA | 51.32 | 37.11 | 22.81 | 14.68 | 10.92 | 7.16 | 4.76 |
| EBITDA margin | +7.3% | +7.4% | +4.9% | +3.2% | +3.1% | +3.7% | +3.2% |
| Profit before tax | 30.54 | 21.64 | 15.24 | 9.49 | 7.13 | 3.57 | 1.71 |
| Net profit | 23.31 | 18.03 | 11.46 | 7.21 | 5.32 | 2.66 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.5% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (βΉ) | 0.97 | 0.66 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Balance sheet | |||||||
| Total assets | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Net worth | 155 | 132 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Total debt | 285 | 175 | 105 | 34.10 | 30.60 | 29.77 | 20.81 |
| Cash & bank | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Net working capital | 291 | 226 | 174 | 101 | 52.62 | 40.86 | 29.38 |
| Cash flow | |||||||
| Cash from operations | (2.30) | (32.32) | 6.01 | (28.79) | (3.82) | 2.77 | 0.51 |
| Cash from investing | (76.29) | (20.62) | (5.49) | (25.65) | (1.46) | (1.29) | (2.53) |
| Cash from financing | 79.17 | 53.35 | (12.10) | 65.93 | 4.26 | (1.49) | (0.28) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 217 | 174 | 221 | 168 | 169 | 145 | 162 | 116 |
| Revenue growth (YoY) | +28.5% | +20.1% | +36.7% | +45.3% | +31.3% | +46.4% | - | - |
| Other income | 1.93 | 1.22 | 4.13 | 1.52 | 1.86 | 1.21 | 0.84 | 0.51 |
| EBITDA | 20.58 | 15.90 | 20.20 | 10.87 | 9.21 | 11.04 | 14.28 | 7.98 |
| EBITDA margin | +9.5% | +9.1% | +9.1% | +6.5% | +5.5% | +7.6% | +8.8% | +6.9% |
| Depreciation | 1.36 | 1.41 | 1.09 | 0.91 | 0.90 | 0.88 | 0.83 | 0.63 |
| Interest | 10.36 | 8.21 | 7.53 | 6.28 | 5.94 | 5.96 | 4.40 | 4.00 |
| Profit before tax | 10.79 | 7.50 | 15.71 | 5.20 | 4.23 | 5.41 | 9.89 | 3.86 |
| Tax | 3.02 | 1.90 | 4.31 | 1.05 | 0.36 | 1.45 | 2.48 | 0.96 |
| Net profit | 7.77 | 5.60 | 11.40 | 4.15 | 3.87 | 3.96 | 7.41 | 2.90 |
| EPS (βΉ) | 0.31 | 0.23 | 0.47 | 0.18 | 0.16 | 0.16 | 0.29 | 0.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 668 | 503 | 466 | 461 | 357 | 193 | 148 |
| Revenue growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| EBITDA | 48.97 | 35.69 | 22.59 | 14.68 | 10.93 | 7.28 | 4.76 |
| EBITDA margin | +7.3% | +7.1% | +4.9% | +3.2% | +3.1% | +3.8% | +3.2% |
| Profit before tax | 28.66 | 21.30 | 15.08 | 9.49 | 7.14 | 3.58 | 1.71 |
| Net profit | 21.97 | 17.98 | 11.34 | 7.21 | 5.33 | 2.67 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.4% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (βΉ) | 0.90 | 0.66 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Balance sheet | |||||||
| Total assets | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Net worth | 153 | 131 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Total debt | 282 | 177 | 107 | 34.10 | 30.59 | 29.78 | 20.81 |
| Cash & bank | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Net working capital | 286 | 229 | 173 | 101 | 52.51 | 40.72 | 29.38 |
| Cash flow | |||||||
| Cash from operations | (2.75) | (33.18) | 9.69 | (28.79) | (3.70) | 2.67 | 0.51 |
| Cash from investing | (79.71) | (20.24) | (9.08) | (25.65) | (1.54) | (1.35) | (2.53) |
| Cash from financing | 82.18 | 53.68 | (12.18) | 65.93 | 4.31 | (1.44) | (0.28) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 205 | 166 | 200 | 158 | 167 | 142 | 162 | 116 |
| Revenue growth (YoY) | +22.8% | +16.4% | +23.7% | +37.0% | +35.1% | +39.9% | - | - |
| Other income | 1.84 | 1.35 | 3.21 | 1.69 | 2.09 | 1.41 | 0.91 | 0.57 |
| Total expenses | 184 | 149 | 182 | 148 | 157 | 132 | 148 | 108 |
| EBITDA | 20.70 | 16.27 | 18.30 | 10.77 | 9.61 | 10.28 | 13.56 | 7.96 |
| EBITDA margin | +10.1% | +9.8% | +9.2% | +6.8% | +5.8% | +7.2% | +8.4% | +6.9% |
| Depreciation | 1.26 | 1.29 | 1.00 | 0.81 | 0.81 | 0.79 | 0.76 | 0.66 |
| Interest | 10.35 | 8.19 | 7.27 | 6.24 | 6.07 | 5.71 | 4.44 | 4.05 |
| Profit before tax | 10.93 | 8.14 | 13.24 | 5.41 | 4.82 | 5.19 | 9.27 | 3.82 |
| Tax | 3.14 | 2.10 | 3.69 | 1.11 | 0.43 | 1.46 | 2.25 | 1.08 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 217 | 174 | 221 | 168 | 169 | 145 | 162 | 116 |
| Revenue growth (YoY) | +28.5% | +20.1% | +36.7% | +45.3% | +31.3% | +46.4% | - | - |
| Other income | 1.93 | 1.22 | 4.13 | 1.52 | 1.86 | 1.21 | 0.84 | 0.51 |
| EBITDA | 20.58 | 15.90 | 20.20 | 10.87 | 9.21 | 11.04 | 14.28 | 7.98 |
| EBITDA margin | +9.5% | +9.1% | +9.1% | +6.5% | +5.5% | +7.6% | +8.8% | +6.9% |
| Depreciation | 1.36 | 1.41 | 1.09 | 0.91 | 0.90 | 0.88 | 0.83 | 0.63 |
| Interest | 10.36 | 8.21 | 7.53 | 6.28 | 5.94 | 5.96 | 4.40 | 4.00 |
| Profit before tax | 10.79 | 7.50 | 15.71 | 5.20 | 4.23 | 5.41 | 9.89 | 3.86 |
| Tax | 3.02 | 1.90 | 4.31 | 1.05 | 0.36 | 1.45 | 2.48 | 0.96 |
| Net profit | 7.77 | 5.60 | 11.40 | 4.15 | 3.87 | 3.96 | 7.41 | 2.90 |
| EPS (βΉ) | 0.31 | 0.23 | 0.47 | 0.18 | 0.16 | 0.16 | 0.29 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 703 | 505 | 464 | 461 | 357 | 193 | 148 |
| Revenue growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| Other income | 8.71 | 2.52 | 2.61 | 1.12 | 0.46 | 0.38 | 0.02 |
| Total expenses | 652 | 468 | 441 | 447 | 346 | 186 | 143 |
| Employee cost | 0.00 | 3.45 | 2.68 | 2.08 | 1.68 | 1.38 | 1.50 |
| EBITDA | 51.32 | 37.11 | 22.81 | 14.68 | 10.92 | 7.16 | 4.76 |
| EBITDA margin | +7.3% | +7.4% | +4.9% | +3.2% | +3.1% | +3.7% | +3.2% |
| Depreciation | 3.79 | 2.22 | 1.24 | 0.91 | 0.87 | 0.74 | 0.35 |
| Interest | 25.70 | 15.77 | 8.94 | 5.40 | 3.38 | 3.23 | 2.72 |
| Profit before tax | 30.54 | 21.64 | 15.24 | 9.49 | 7.13 | 3.57 | 1.71 |
| Tax | 7.16 | 5.68 | 3.78 | 2.46 | 1.88 | 0.91 | 0.44 |
| Net profit | 23.31 | 18.03 | 11.46 | 7.21 | 5.32 | 2.66 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.5% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (βΉ) | 0.97 | 0.66 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.07 | 24.07 | 24.07 | 24.07 | 9.75 | 9.55 | 9.55 |
| Reserves & surplus | 127 | 104 | 87.64 | 76.91 | 20.03 | 12.96 | 10.29 |
| Shareholders' funds (net worth) | 155 | 132 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Minority interest | 1.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
| Secured loans | 226 | 147 | 68.98 | 31.04 | 27.38 | 4.36 | 14.70 |
| Unsecured loans | 59.38 | 27.23 | 35.86 | 3.06 | 3.22 | 25.41 | 6.11 |
| Total debt | 285 | 175 | 105 | 34.10 | 30.60 | 29.77 | 20.81 |
| Total liabilities | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Assets | |||||||
| Gross block | 110 | 50.31 | 29.33 | 22.45 | 8.49 | 7.64 | 6.32 |
| Net block | 104 | 47.50 | 25.50 | 19.89 | 6.46 | 6.22 | 5.64 |
| Capital work in progress | 3.44 | 22.54 | 1.88 | 0.01 | 0.54 | 0.00 | 0.00 |
| Investments | 0.00 | 1.67 | 13.84 | 12.34 | 0.00 | 0.00 | 0.04 |
| Inventories | 219 | 140 | 85.74 | 74.57 | 46.87 | 23.96 | 17.38 |
| Sundry debtors | 233 | 153 | 123 | 81.51 | 73.48 | 60.39 | 26.87 |
| Cash & bank balances | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Loans & advances | 37.05 | 32.14 | 31.64 | 30.83 | 9.00 | 2.03 | 1.34 |
| Total current assets | 490 | 326 | 240 | 199 | 130 | 87.63 | 46.86 |
| Total current liabilities | 200 | 99.33 | 66.48 | 97.16 | 76.97 | 46.77 | 17.48 |
| Net working capital | 291 | 226 | 174 | 101 | 52.62 | 40.86 | 29.38 |
| Total assets | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 | 3.56 |
| Net cash from operating activities | (2.30) | (32.32) | 6.01 | (28.79) | (3.82) | 2.77 | 0.51 |
| Net cash from investing activities | (76.29) | (20.62) | (5.49) | (25.65) | (1.46) | (1.29) | (2.53) |
| Net cash from financing activities | 79.17 | 53.35 | (12.10) | 65.93 | 4.26 | (1.49) | (0.28) |
| Net change in cash | 0.58 | 0.41 | (11.58) | 11.48 | (1.02) | (0.01) | (2.29) |
| Closing cash | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| EBITDA growth | +38.3% | +62.7% | +55.4% | +34.4% | +52.5% | +50.4% | - |
| PBT growth | +52.4% | +31.5% | +60.6% | +33.1% | +99.7% | +108.8% | +9997.0% |
| Net income growth | +29.3% | +57.3% | +59.0% | +35.5% | +100.0% | +109.5% | - |
| Revenue CAGR (3Y) | +15.1% | +12.3% | +33.8% | +46.1% | - | - | - |
| EBITDA CAGR (3Y) | +51.8% | +49.2% | +47.1% | +45.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +3.0% | +2.5% | +1.5% | +1.5% | +1.4% | +0.9% |
| Return on capital employed | +15.1% | +14.9% | +13.7% | +15.2% | +18.7% | +14.6% | +10.9% |
| Return on net worth | +16.3% | +14.0% | +10.8% | +10.8% | +20.1% | +12.6% | +6.5% |
| Debt / equity | 1.60 | 1.15 | 0.65 | 0.49 | 1.15 | 1.19 | 1.05 |
| Long-term debt / equity | 0.15 | 0.10 | 0.11 | 0.14 | 0.20 | 0.29 | 0.35 |
| Interest cover | 54.08 | 48.00 | 41.45 | 39.22 | 33.63 | 50.31 | 61.68 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 8.78 | 12.68 | 17.90 | 29.82 | 44.28 | 27.70 | 23.41 |
| Inventory turnover | 3.91 | 4.47 | 5.78 | 7.60 | 10.08 | 9.35 | 8.51 |
| Debtors turnover | 3.64 | 3.67 | 4.54 | 5.95 | 5.33 | 4.43 | 5.51 |
| EPS (βΉ) | 0.97 | 0.62 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 6.29 | 5.32 | 46.42 | 41.96 | 30.54 | 23.58 | 20.78 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 205 | 166 | 200 | 158 | 167 | 142 | 162 | 116 |
| Revenue growth (YoY) | +22.8% | +16.4% | +23.7% | +37.0% | +35.1% | +39.9% | - | - |
| Other income | 1.84 | 1.35 | 3.21 | 1.69 | 2.09 | 1.41 | 0.91 | 0.57 |
| Total expenses | 184 | 149 | 182 | 148 | 157 | 132 | 148 | 108 |
| EBITDA | 20.70 | 16.27 | 18.30 | 10.77 | 9.61 | 10.28 | 13.56 | 7.96 |
| EBITDA margin | +10.1% | +9.8% | +9.2% | +6.8% | +5.8% | +7.2% | +8.4% | +6.9% |
| Depreciation | 1.26 | 1.29 | 1.00 | 0.81 | 0.81 | 0.79 | 0.76 | 0.66 |
| Interest | 10.35 | 8.19 | 7.27 | 6.24 | 6.07 | 5.71 | 4.44 | 4.05 |
| Profit before tax | 10.93 | 8.14 | 13.24 | 5.41 | 4.82 | 5.19 | 9.27 | 3.82 |
| Tax | 3.14 | 2.10 | 3.69 | 1.11 | 0.43 | 1.46 | 2.25 | 1.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 668 | 503 | 466 | 461 | 357 | 193 | 148 |
| Revenue growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| Other income | 8.40 | 2.88 | 2.75 | 1.12 | 0.46 | 0.27 | 0.02 |
| Total expenses | 619 | 467 | 443 | 447 | 346 | 186 | 143 |
| Employee cost | 0.00 | 3.12 | 2.54 | 2.08 | 1.68 | 1.38 | 1.50 |
| EBITDA | 48.97 | 35.69 | 22.59 | 14.68 | 10.93 | 7.28 | 4.76 |
| EBITDA margin | +7.3% | +7.1% | +4.9% | +3.2% | +3.1% | +3.8% | +3.2% |
| Depreciation | 3.41 | 1.31 | 1.23 | 0.91 | 0.87 | 0.74 | 0.35 |
| Interest | 25.30 | 15.96 | 9.03 | 5.40 | 3.38 | 3.23 | 2.72 |
| Profit before tax | 28.66 | 21.30 | 15.08 | 9.49 | 7.14 | 3.58 | 1.71 |
| Tax | 6.69 | 5.41 | 3.74 | 2.46 | 1.88 | 0.91 | 0.44 |
| Net profit | 21.97 | 17.98 | 11.34 | 7.21 | 5.33 | 2.67 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.4% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (βΉ) | 0.90 | 0.66 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.07 | 24.07 | 24.07 | 24.07 | 9.75 | 9.55 | 9.55 |
| Reserves & surplus | 125 | 103 | 87.55 | 76.92 | 20.03 | 12.96 | 10.29 |
| Shareholders' funds (net worth) | 153 | 131 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Secured loans | 224 | 147 | 68.98 | 31.40 | 27.38 | 25.72 | 14.70 |
| Unsecured loans | 58.22 | 29.26 | 37.91 | 2.70 | 3.21 | 4.06 | 6.11 |
| Total debt | 282 | 177 | 107 | 34.10 | 30.59 | 29.78 | 20.81 |
| Total liabilities | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Assets | |||||||
| Gross block | 99.50 | 45.03 | 24.36 | 22.45 | 8.49 | 7.64 | 6.32 |
| Net block | 94.25 | 42.33 | 20.57 | 19.89 | 6.46 | 6.22 | 5.64 |
| Capital work in progress | 3.44 | 22.54 | 1.88 | 0.01 | 0.54 | 0.00 | 0.00 |
| Investments | 7.75 | 4.84 | 16.94 | 12.44 | 0.10 | 0.09 | 0.04 |
| Inventories | 207 | 137 | 84.37 | 74.57 | 46.87 | 23.96 | 17.38 |
| Sundry debtors | 199 | 152 | 123 | 81.51 | 73.48 | 60.39 | 26.87 |
| Cash & bank balances | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Loans & advances | 38.75 | 35.27 | 31.78 | 30.73 | 8.90 | 1.99 | 1.34 |
| Total current assets | 445 | 325 | 239 | 199 | 129 | 87.49 | 46.86 |
| Total current liabilities | 158 | 95.40 | 65.87 | 97.16 | 76.97 | 46.77 | 17.48 |
| Net working capital | 286 | 229 | 173 | 101 | 52.51 | 40.72 | 29.38 |
| Total assets | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 | 3.56 |
| Net cash from operating activities | (2.75) | (33.18) | 9.69 | (28.79) | (3.70) | 2.67 | 0.51 |
| Net cash from investing activities | (79.71) | (20.24) | (9.08) | (25.65) | (1.54) | (1.35) | (2.53) |
| Net cash from financing activities | 82.18 | 53.68 | (12.18) | 65.93 | 4.31 | (1.44) | (0.28) |
| Net change in cash | (0.28) | 0.26 | (11.58) | 11.48 | (0.93) | (0.11) | (2.29) |
| Closing cash | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| EBITDA growth | +37.2% | +58.0% | +53.9% | +34.3% | +50.1% | +52.9% | - |
| PBT growth | +52.4% | +24.7% | +58.9% | +32.9% | +99.4% | +109.4% | -47.7% |
| Net income growth | +22.2% | +58.6% | +57.3% | +35.3% | +99.6% | +110.2% | - |
| Revenue CAGR (3Y) | +13.1% | +12.1% | +34.0% | +46.1% | +36.9% | +29.9% | +38.8% |
| EBITDA CAGR (3Y) | +49.4% | +47.0% | +45.9% | +45.6% | +36.1% | +141.0% | +98.4% |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +2.8% | +2.4% | +1.5% | +1.5% | +1.4% | +0.9% |
| Return on capital employed | +14.5% | +14.4% | +13.6% | +15.2% | +18.7% | +14.6% | +12.0% |
| Return on net worth | +15.5% | +13.2% | +10.7% | +10.8% | +20.1% | +12.6% | +6.6% |
| Debt / equity | 1.62 | 1.17 | 0.66 | 0.49 | 1.15 | 1.19 | 0.91 |
| Long-term debt / equity | 0.16 | 0.10 | 0.11 | 0.14 | 0.20 | 0.36 | 0.30 |
| Interest cover | 55.54 | 50.66 | 42.28 | 39.22 | 33.60 | 49.39 | 61.68 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 9.24 | 14.48 | 19.89 | 29.82 | 36.12 | 27.70 | 34.41 |
| Inventory turnover | 3.88 | 4.54 | 5.86 | 7.60 | 10.08 | 9.35 | 10.65 |
| Debtors turnover | 3.80 | 3.65 | 4.55 | 5.95 | 5.33 | 4.43 | 5.61 |
| EPS (βΉ) | 0.91 | 0.58 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 6.19 | 5.27 | 46.38 | 41.96 | 30.55 | 23.58 | 20.78 |
Investments & Acquisitions by Sudarshan Pharma
Sudarshan Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ishwari Healthcare.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Medical supplies and consumables are manufactured in a range. | ishwarihealthcare.com | Mumbai, India | 1998 | Oct 2024 | β’β’β’β’ |
Complete acquisition details for Sudarshan Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sudarshan Pharma
4 dated milestones of Sudarshan Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Sudarshan Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Ishwari Healthcare.
- Funding First funding round of $450K.
Web traffic of Sudarshan Pharma
The website of Sudarshan Pharma (sudarshanpharma.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▼ 73.6% vs previous month
Websites whose visitors overlap most with Sudarshan Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| balaxipharma.in | 100% | 1.9K | #8,042,738 | View details |
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Sudarshan Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sudarshan Pharma
Complete news archive for Sudarshan Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sudarshan Pharma
Sudarshan Pharma was founded in 2008 and raised its 1st funding round 16 years after it was founded.
Sudarshan Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Sudarshan Pharma has 24 employees.
The primary company behind Sudarshan Pharma, Sudarshan Pharma Industries Limited, reported revenue of βΉ712 Cr for FY 2026, up 39% year on year.
Sudarshan Pharma Industries Limited is involved in the production of pharmaceuticals and specialty chemicals. Operations are focused on active pharmaceutical ingredients (API), intermediates, and contract manufacturing. The company serves various sectors including healthcare and industrial applications. Solutions are provided for ethical divisions, generic supply, and institutional markets. Manufacturing facilities are located across multiple states in India, with distribution outlets in key regions. Exports of APIs and formulations are also managed to international markets.
Sudarshan Pharma offers Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing.
Yes, Sudarshan Pharma is publicly traded on BSE under the ticker symbol SUDARSHAN.
Sudarshan Pharma has made 1 acquisition, including Ishwari Healthcare.
Sudarshan Pharma operates through Sudarshan Pharma Industries Limited.
The legal entities of Sudarshan Pharma currently have 9 directors, including Sachin Vasantrai Mehta, Jaya Ankur Singhania, Hemal Vasantrai Mehta and others.
